Day 2 - Wednesday, November 19, 2025Wednesday, 19 November 2025 - ET (Eastern Time, GMT-05:00)

What return can you expect from an investment in patient access and affordability programs if eligible patients aren’t aware of them? During this session, explore practical steps to increasing your brand’s “Activation Quotient” starting today, extending your programs’ reach, increasing enrollment and utilization, and ultimately improving patient outcomes.

• Understand the necessity of proactive activation for patient affordability programs to effectively increase patient participation

• Leverage external partners to more efficiently reach, identify, and screen eligible patients—at scale

• Measure and demonstrate successful integration of medication affordability programs within pharma + partner ecosystems

• Overcome common barriers to activation, including lack of data standardization, low patient engagement, and inconsistent technology integration

Industry experts will break down the most critical IRA developments, explore how manufacturers are adapting and discuss what’s next as additional policy changes take effect.

• Receive an update on how the IRA has reshaped market access and patient services so far

• Check in on the progress of Medicare Part D, including patient adoption rates and how the new structure affects copay programs, patient assistance and manufacturer cost exposure

• Benchmark with industry peers to hear how other manufacturers are restructuring their patient support programs in response to IRA

• Learn how IRA provisions will continue to evolve through 2026 and beyond to inform long-term strategic adjustments

This session will look in depth at common problems including growing demand for specialty medications, state regulations and impact on patient access to specialty drugs and how patients will cope with rising costs of medications. Our session will focus on solutions for these common problems by exploring integrated care models for savings, patient education that reflects the policy changes and how to responsibly implement AI in the patient journey.

The accumulator, maximizer, and alternative funding program landscape is rapidly evolving, creating new hurdles for manufacturers aiming to preserve patient affordability.

• Gain insights into the future of accumulators and maximizers and whether regulatory changes could shift payer and PBM cost-containment strategies

• Navigate the growing patchwork of state laws impacting copay programs and assess risk mitigation strategies for long-term sustainability

Gain key insights on enforcement trends and upcoming areas of focus for 2025 and beyond, specifically looking at guidance on field-based roles, prior authorization and carveout watch-outs.

In an era of increasing payer restrictions, evolving reimbursement models and shifting patient affordability challenges, how manufacturers communicate about copay and patient support programs is more critical than ever. This session explores how manufacturers can strike the right balance between proactive and reactive communication to enhance stakeholder education, patient engagement and program success.

• Learn strategies on how to evaluate the utilization and effectiveness of FRMs

• Uncover opportunities to increase customer satisfaction

• Understand risk areas, such as sourcing and sharing data, and how to mitigate compliantly

• Identify key challenges, such as cost sharing programs, and how to train FRMs accordingly

This session explores the complexities of operationalizing specialty pharmacy in Rare Disease, with a focus on balancing patient access with market considerations for physician-administered therapies. Address the challenges manufacturers face in navigating payer policies and managing medical versus pharmacy benefit access.

• Run through the advantages and challenges associated with specialty pharmacy in rare disease, including strategies for effective operationalization

• Navigate the patient journey through medical billing, copay programs and their impact on treatment access

• Balance buy-and-bill vs. specialty pharmacy channels for physician-administered therapies in rare diseases

• Uncover strategies for manufacturers to collaborate with specialty pharmacies to navigate payer policies and optimize patient support programs